Neurological symptoms and blood neurofilament light levels

Author(s):  
Christian Barro ◽  
Henrik Zetterberg
2017 ◽  
Vol 49 ◽  
pp. 138-144 ◽  
Author(s):  
Ane-Victoria Idland ◽  
Roser Sala-Llonch ◽  
Tom Borza ◽  
Leiv Otto Watne ◽  
Torgeir Bruun Wyller ◽  
...  

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Michael Khalil ◽  
Lukas Pirpamer ◽  
Edith Hofer ◽  
Margarete M. Voortman ◽  
Christian Barro ◽  
...  

Author(s):  
Christiana Franke ◽  
Caroline Ferse ◽  
Jakob Kreye ◽  
S Momsen Reincke ◽  
Elisa Sanchez-Sendin ◽  
...  

AbstractCOVID-19 intensive care patients occasionally develop neurological symptoms. The absence of SARS-CoV-2 in most cerebrospinal fluid (CSF) samples suggests the involvement of further mechanisms including autoimmunity. We therefore determined whether anti-neuronal or anti-glial autoantibodies are present in eleven consecutive severely ill COVID-19 patients presenting with unexplained neurological symptoms. These included myoclonus, cranial nerve involvement, oculomotor disturbance, delirium, dystonia and epileptic seizures. Most patients showed signs of CSF inflammation and increased levels of neurofilament light chain. All patients had anti-neuronal autoantibodies in serum or CSF when assessing a large panel of autoantibodies against intracellular and surface antigens relevant for central nervous system diseases using cell-based assays and indirect immunofluorescence on murine brain sections. Antigens included proteins well-established in clinical routine, such as Yo or NMDA receptor, but also a variety of specific undetermined epitopes on brain sections. These included vessel endothelium, astrocytic proteins and neuropil of basal ganglia, hippocampus or olfactory bulb. The high frequency of autoantibodies targeting the brain in the absence of other explanations suggests a causal relationship to clinical symptoms, in particular to hyperexcitability (myoclonus, seizures). While several underlying autoantigens still await identification in future studies, presence of autoantibodies may explain some aspects of multi-organ disease in COVID-19 and can guide immunotherapy in selected cases.


2017 ◽  
Vol 13 (7) ◽  
pp. P207
Author(s):  
Elizabeth E. Moore ◽  
Timothy J. Hohman ◽  
Faizan Badami ◽  
Kimberly R. Pechman ◽  
Elizabeth A. Gordon ◽  
...  

2020 ◽  
Vol 3 (11) ◽  
pp. e2016278
Author(s):  
Tatiana Plavina ◽  
Carol M. Singh ◽  
Dipen Sangurdekar ◽  
Carl de Moor ◽  
Bob Engle ◽  
...  

2006 ◽  
Vol 14 (7S_Part_5) ◽  
pp. P315-P315
Author(s):  
Ruth E. Droege ◽  
Stephan A. Kaeser ◽  
Juliane Schelle ◽  
Lisa M. Haesler ◽  
Rawaa Al-Shaana ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document